文献速递疝与腹壁外科围术期管理与 ERAS

COPD患者腹壁手术前肉毒毒素注射与术后呼吸系统并发症的多中心研究

Postoperative respiratory morbidity in chronic obstructive pulmonary disease patients receiving botulinum toxin injection before abdominal wall surgery: A multicentric study.
PubMed 文献 · Surgery · 2025-09-30

该多中心横断面研究纳入2013至2024年4家中心连续接受腹壁手术的慢性阻塞性肺疾病(COPD)患者150例,其中60例(40%)术前接受肉毒毒素A注射、90例未接受。两组术后肺炎发生率相似(3/60 vs 4/90,P=.874),多变量分析中仅组织结构分离是肺炎的预测因素(OR 8.7,95%CI 1.7-44.9,P=.010),肉毒毒素A不是(OR 0.9,95%CI 0.2-4.0,P=.920)。就术后呼吸系统并发症而言,COPD患者腹壁手术前使用肉毒毒素A似乎是安全的。

要点

  • COPD患者腹壁手术前肉毒毒素A注射未增加术后肺炎发生率。
  • 肉毒毒素A组腹壁缺损更大、更多患者存在loss of domain,两组基线不均衡。
  • 多变量分析中组织结构分离是术后肺炎的唯一预测因素。

核心结论

  • 就术后呼吸系统并发症而言,COPD患者接受腹壁手术前使用肉毒毒素A似乎是安全的。
  • 肉毒毒素A注射并非术后肺炎的预测因素(OR 0.9,95%CI 0.2-4.0,P=.920)。
  • 组织结构分离是术后肺炎的唯一预测因素(OR 8.7,95%CI 1.7-44.9,P=.010)。

研究设计与样本

  • 多中心(4个中心)横断面研究,纳入2013-2024年连续接受腹壁手术的COPD患者。
  • 共纳入150例COPD患者,中位年龄68岁(四分位距63-73),女性61例(41%),中位体重指数29 kg/m2(四分位距25-33 kg/m2)。
  • 60例(40%)接受肉毒毒素A注射,90例(60%)未接受;大型或复杂疝者在术前4-8周视需要注射肉毒毒素A。
  • COPD依据麻醉术前会诊定义,主要终点为术后医院获得性肺炎发生率。

主要发现

  • 肉毒毒素A组loss of domain患者比例更高(28% vs 7%,P<.001),中位缺损尺寸更大(12 vs 6 cm,P<.001)。
  • 术后并发症在肉毒毒素A组为26例(43%)、非肉毒毒素A组为33例(37%)(P=.413)。
  • 术后肺炎发生率两组相似(3/60 vs 4/90,P=.874)。

关键数值与推荐

  • COPD依据麻醉术前会诊定义。
  • 大型或复杂疝患者在术前4-8周视需要接受肉毒毒素A注射。
  • 主要终点为术后医院获得性肺炎发生率。

临床怎么用

  • 对合并COPD的腹壁疝患者,术前肉毒毒素A注射在呼吸系统并发症方面可考虑使用。
  • 围术期呼吸风险管理应重点关注需行组织结构分离的患者。
  • 术前评估COPD并个体化决定是否注射肉毒毒素A,需结合疝的复杂程度。

局限性

  • 为横断面研究设计,组间基线不均衡(肉毒毒素A组缺损更大、loss of domain更多)。
  • 样本量有限(共150例),肺炎事件数少。
  • COPD定义依赖麻醉术前会诊,未报告肺功能分级等细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Botulinum toxin A injection is often used before abdominal wall surgery. Because botulinum toxin A inhibits the lateral abdominal muscles that have a secondary role in the breathing biomechanics, potential concerns regarding postoperative respiratory morbidity in patients with chronic obstructive pulmonary disease have been raised. This study assessed the incidence of postoperative pneumonias after abdominal wall surgery in patients with chronic obstructive pulmonary disease with and without botulinum toxin A injection. METHODS: A multicentric (4 centers) cross-sectional study was performed. Consecutive patients with chronic obstructive pulmonary disease who underwent abdominal wall surgery (2013-2024) were included. In case of large or complex hernia, botulinum toxin A was performed 4-8 weeks before surgery if judged necessary. Chronic obstructive pulmonary disease was defined based on the anesthesia preoperative consultation. The primary end point was the rate of postoperative hospital-acquired pneumonias. RESULTS: A total of 150 patients with chronic obstructive pulmonary disease were included: median age 68 years (interquartile range: 63-73), 61 women (41%), and median body mass index 29 kg/m2 (interquartile range: 25-33 kg/m2). Sixty patients received botulinum toxin A (40%), and 90 did not receive botulinum toxin A (60%). In the botulinum toxin A group, more patients had loss of domain (28% vs 7%, P < .001), and the median defect size was larger (12 vs 6 cm, P < .001). Fifty-four (90%) and 61 (68%) patients had midline incisional hernias in the botulinum toxin A and non-botulinum toxin A groups (P = .006). Postoperative complications occurred in 26 patients in the botulinum toxin A group (43%) and 33 patients in the non-botulinum toxin A group (37%, P = .413). Postoperative pneumonia incidences were similar in both groups (3/60 vs 4/90, P = .874). On multivariable analysis, component separation was the only predictor of pneumonia (odds ratio: 8.7, 95% confidence interval: 1.7-44.9, P = .010) and not botulinum toxin A (odds ratio: 0.9, 95% confidence interval: 0.2-4.0, P = .920). CONCLUSION: Regarding postoperative respiratory morbidity, botulinum toxin A seems safe in patients with chronic obstructive pulmonary disease undergoing abdominal wall surgery.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Joliat GR, Ortega-Deballon P, Alsuwaidan H, et al. Postoperative respiratory morbidity in chronic obstructive pulmonary disease patients receiving botulinum toxin injection before abdominal wall surgery: A multicentric study. Surgery. 2025. PMID: 41033266. doi:10.1016/j.surg.2025.109765

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。